Works matching AU Ogawa, Chikara

Results: 90
    1
    2

    Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.

    Published in:
    Liver International, 2025, v. 45, n. 7, p. 1, doi. 10.1111/liv.70192
    By:
    • Hatanaka, Takeshi;
    • Yata, Yutaka;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Kakizaki, Satoru;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Koshiyama, Yuichi;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi
    Publication type:
    Article
    3
    4

    Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.

    Published in:
    Oncology, 2023, v. 101, n. 10, p. 624, doi. 10.1159/000531316
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    5

    Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.

    Published in:
    Oncology, 2023, v. 101, n. 9, p. 542, doi. 10.1159/000530028
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    6

    Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.

    Published in:
    Oncology, 2023, v. 101, n. 4, p. 270, doi. 10.1159/000527676
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Hirooka, Masashi;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Fukunishi, Shinya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Ogawa, Chikara;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Nishimura, Takashi;
    • Kakizaki, Satoru
    Publication type:
    Article
    7

    Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.

    Published in:
    Oncology, 2022, v. 100, n. 12, p. 645, doi. 10.1159/000526521
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    8

    Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.

    Published in:
    Oncology, 2017, v. 93, p. 113, doi. 10.1159/000481241
    By:
    • Ogawa, Chikara;
    • Morita, Masahiro;
    • Omura, akina;
    • Noda, Teruyo;
    • Kubo, atsushi;
    • Matsunaka, Toshihiro;
    • Tamaki, Hiroyuki;
    • Shibatoge, Mitsushige;
    • Tsutsui, akemi;
    • Senoh, Tomonori;
    • Nagano, Takuya;
    • Takaguchi, Kouichi;
    • Tani, Joji;
    • Morishita, asahiro;
    • Yoneyama, Hirohito;
    • Masaki, Tsutomu;
    • Moriya, akio;
    • ando, Masaharu;
    • Deguchi, akihiro;
    • Kokudo, Yasutaka
    Publication type:
    Article
    9
    10
    11
    12

    A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 1, p. 99, doi. 10.1159/000531377
    By:
    • Kudo, Masatoshi;
    • Ueshima, Kazuomi;
    • Saeki, Issei;
    • Ishikawa, Toru;
    • Inaba, Yoshitaka;
    • Morimoto, Naoki;
    • Aikata, Hiroshi;
    • Tanabe, Nobukazu;
    • Wada, Yoshiyuki;
    • Kondo, Yasuteru;
    • Tsuda, Masahiro;
    • Nakao, Kazuhiko;
    • Ito, Takanori;
    • Hosaka, Tetsuya;
    • Kawamura, Yusuke;
    • Kuzuya, Teiji;
    • Nojiri, Shunsuke;
    • Ogawa, Chikara;
    • Koga, Hironori;
    • Hino, Keisuke
    Publication type:
    Article
    13

    Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 4, p. 321, doi. 10.1159/000529574
    By:
    • Kudo, Masatoshi;
    • Aoki, Tomoko;
    • Ueshima, Kazuomi;
    • Tsuchiya, Kaoru;
    • Morita, Masahiro;
    • Chishina, Hirokazu;
    • Takita, Masahiro;
    • Hagiwara, Satoru;
    • Minami, Yasunori;
    • Ida, Hiroshi;
    • Nishida, Naoshi;
    • Ogawa, Chikara;
    • Tomonari, Tetsu;
    • Nakamura, Noriaki;
    • Kuroda, Hidekatsu;
    • Takebe, Atsushi;
    • Takeyama, Yoshifumi;
    • Hidaka, Masaaki;
    • Eguchi, Susumu;
    • Chan, Stephen L
    Publication type:
    Article
    14

    Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.

    Published in:
    Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    15

    Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 1, p. 50, doi. 10.1159/000502744
    By:
    • Maeda, Masaki;
    • Saeki, Issei;
    • Sakaida, Isao;
    • Aikata, Hiroshi;
    • Araki, Yasuyuki;
    • Ogawa, Chikara;
    • Kariyama, Kazuya;
    • Nouso, Kazuhiro;
    • Kitamoto, Mikiya;
    • Kobashi, Haruhiko;
    • Sato, Shuichi;
    • Shibata, Hiroshi;
    • Joko, Kouji;
    • Takaki, Shintaro;
    • Takabatake, Hiroyuki;
    • Tsutsui, Akemi;
    • Takaguchi, Koichi;
    • Tomonari, Tetsu;
    • Nakamura, Shinichiro;
    • Nagahara, Takakazu
    Publication type:
    Article
    16

    Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 10, p. 1361, doi. 10.1111/apt.18237
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    17

    Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 233, doi. 10.1111/apt.18037
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Kawata, Kazuhito
    Publication type:
    Article
    18

    Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

    Published in:
    Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-024-78539-4
    By:
    • Ohama, Hideko;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    19

    The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 9, p. 1230, doi. 10.1111/apt.15218
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Toyoda, Hidenori;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Watanabe, Tsunamasa;
    • Michitaka, Kojiro;
    • Ikegami, Tadashi;
    • Nozaki, Akito;
    • Uojima, Haruki;
    • Fukunishi, Shinya;
    • Genda, Takuya;
    • Abe, Hiroshi;
    • Hotta, Naoki;
    • Tsuji, Kunihiko;
    • Ogawa, Chikara;
    • Tachi, Yoshihiko;
    • Shima, Toshihide;
    • Shimada, Noritomo;
    • Kondo, Chisa
    Publication type:
    Article
    20

    Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.

    Published in:
    JGH Open, 2024, v. 8, n. 4, p. 1, doi. 10.1002/jgh3.13068
    By:
    • Morita, Atsuhiro;
    • Tamaki, Nobuharu;
    • Kobashi, Haruhiko;
    • Mori, Nami;
    • Tsuji, Keiji;
    • Takaki, Shintaro;
    • Hasebe, Chitomi;
    • Akahane, Takehiro;
    • Ochi, Hironori;
    • Mashiba, Toshie;
    • Urawa, Naohito;
    • Fujii, Hideki;
    • Mitsuda, Akeri;
    • Kondo, Masahiko;
    • Ogawa, Chikara;
    • Uchida, Yasushi;
    • Narita, Ryoichi;
    • Marusawa, Hiroyuki;
    • Kubotsu, Yoshihito;
    • Matsushita, Tomomichi
    Publication type:
    Article
    21
    22

    Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.

    Published in:
    JGH Open, 2021, v. 5, n. 1, p. 34, doi. 10.1002/jgh3.12443
    By:
    • Itokawa, Norio;
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Hiraoka, Atsushi;
    • Kato, Keizo;
    • Abe, Hiroshi;
    • Mikami, Shigeru;
    • Shimada, Noritomo;
    • Chuma, Makoto;
    • Akito, Nozaki;
    • Uojima, Haruki;
    • Ogawa, Chikara;
    • Asano, Toru;
    • Tani, Joji;
    • Morishita, Asahiro;
    • Senoh, Tomonori;
    • Yamashita, Naoki;
    • Oikawa, Tsunekazu
    Publication type:
    Article
    23
    24

    Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.

    Published in:
    PLoS ONE, 2016, v. 11, n. 10, p. 1, doi. 10.1371/journal.pone.0165339
    By:
    • Itakura, Jun;
    • Kurosaki, Masayuki;
    • Hasebe, Chitomi;
    • Osaki, Yukio;
    • Joko, Kouji;
    • Yagisawa, Hitoshi;
    • Sakita, Shinya;
    • Okushin, Hiroaki;
    • Satou, Takashi;
    • Hisai, Hiroyuki;
    • Abe, Takehiko;
    • Tsuji, Keiji;
    • Tamada, Takashi;
    • Kobashi, Haruhiko;
    • Mitsuda, Akeri;
    • Ide, Yasushi;
    • Ogawa, Chikara;
    • Tsuruta, Syotaro;
    • Takaguchi, Kouichi;
    • Murakawa, Miyako
    Publication type:
    Article
    25

    Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.

    Published in:
    Gastroenterology Report, 2021, v. 9, n. 2, p. 133, doi. 10.1093/gastro/goaa042
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Ogawa, Chikara;
    • Tani, Joji;
    • Fukunishi, Shinya;
    • Atsukawa, Masanori;
    • Hirooka, Masashi;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Takaguchi, Koichi;
    • Kariyama, Kazuya;
    • Itobayashi, Ei;
    • Tajiri, Kazuto;
    • Shimada, Noritomo;
    • Shibata, Hiroshi;
    • Ochi, Hironori;
    • Kawata, Kazuhito;
    • Toyoda, Hidenori;
    • Ohama, Hideko
    Publication type:
    Article
    26

    Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab–Treated HCC.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 949, doi. 10.1111/jgh.16884
    By:
    • Matono, Tomomitsu;
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Nishikawa, Hiroki;
    • Tanaka, Kazunari;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Koshiyama, Yuichi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Hatanaka, Takeshi
    Publication type:
    Article
    27

    Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models.

    Published in:
    Journal of Gastroenterology & Hepatology, 2025, v. 40, n. 4, p. 930, doi. 10.1111/jgh.16871
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    28

    Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

    Published in:
    Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 8, p. 1389, doi. 10.1111/jgh.16225
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    29

    Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.

    Published in:
    Journal of Gastroenterology & Hepatology, 2019, v. 34, n. 2, p. 364, doi. 10.1111/jgh.14447
    By:
    • Atsukawa, Masanori;
    • Kondo, Chisa;
    • Iwakiri, Katsuhiko;
    • Asano, Toru;
    • Ishikawa, Toru;
    • Abe, Hiroshi;
    • Kato, Keizo;
    • Tsuji, Kunihiko;
    • Ogawa, Chikara;
    • Shimada, Noritomo;
    • Iio, Etsuko;
    • Tanaka, Yasuhito;
    • Mikami, Shigeru;
    • Tsubota, Akihito;
    • Matsumoto, Yoshihiro;
    • Toyoda, Hidenori;
    • Kumada, Takashi;
    • Takaguchi, Koichi;
    • Okubo, Tomomi;
    • Hiraoka, Atsushi
    Publication type:
    Article
    30
    31

    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

    Published in:
    PLoS ONE, 2018, v. 13, n. 4, p. 1, doi. 10.1371/journal.pone.0194704
    By:
    • Mashiba, Toshie;
    • Joko, Kouji;
    • Kurosaki, Masayuki;
    • Ochi, Hironori;
    • Osaki, Yukio;
    • Kojima, Yuji;
    • Nakata, Ryo;
    • Goto, Tohru;
    • Takehiro, Akahane;
    • Kimura, Hiroyuki;
    • Mitsuda, Akeri;
    • Kawanami, Chiharu;
    • Uchida, Yasushi;
    • Ogawa, Chikara;
    • Kusakabe, Atsunori;
    • Narita, Ryuichi;
    • Ide, Yasushi;
    • Abe, Takehiko;
    • Tsuji, Keiji;
    • Kitamura, Tadashi
    Publication type:
    Article
    32
    33

    Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.

    Published in:
    Digestive Endoscopy, 2016, v. 28, n. 1, p. 67, doi. 10.1111/den.12553
    By:
    • Tamaki, Hiroyuki;
    • Nakase, Hiroshi;
    • Inoue, Satoko;
    • Kawanami, Chiharu;
    • Itani, Toshinao;
    • Ohana, Masaya;
    • Kusaka, Toshihiro;
    • Uose, Suguru;
    • Hisatsune, Hiroshi;
    • Tojo, Masahide;
    • Noda, Teruyo;
    • Arasawa, Souichi;
    • Izuta, Masako;
    • Kubo, Atsushi;
    • Ogawa, Chikara;
    • Matsunaka, Toshihiro;
    • Shibatouge, Mitsushige
    Publication type:
    Article
    34

    Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.

    Published in:
    Infectious Diseases & Therapy, 2020, v. 9, n. 4, p. 851, doi. 10.1007/s40121-020-00329-y
    By:
    • Atsukawa, Masanori;
    • Tsubota, Akihito;
    • Kondo, Chisa;
    • Toyoda, Hidenori;
    • Nakamuta, Makoto;
    • Takaguchi, Koichi;
    • Watanabe, Tsunamasa;
    • Hiraoka, Atsushi;
    • Uojima, Haruki;
    • Ishikawa, Toru;
    • Iwasa, Motoh;
    • Tada, Toshifumi;
    • Nozaki, Akito;
    • Chuma, Makoto;
    • Fukunishi, Shinya;
    • Asai, Akira;
    • Asano, Toru;
    • Ogawa, Chikara;
    • Abe, Hiroshi;
    • Hotta, Naoki
    Publication type:
    Article
    35

    Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group

    Published in:
    Journal of Viral Hepatitis, 2022, v. 29, n. 7, p. 551, doi. 10.1111/jvh.13684
    By:
    • Mashiba, Toshie;
    • Joko, Kouji;
    • Kurosaki, Masayuki;
    • Ochi, Hironori;
    • Marusawa, Hiroyuki;
    • Uchida, Yasushi;
    • Fujii, Hideki;
    • Kojima, Yuji;
    • Yoshida, Hideo;
    • Goto, Tohru;
    • Akahane, Takehiro;
    • Kondo, Masahiko;
    • Tsuji, Keiji;
    • Mitsuda, Akeri;
    • Hasebe, Chitomi;
    • Kusakabe, Atsunori;
    • Sohda, Tetsuro;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Ogawa, Chikara
    Publication type:
    Article
    36

    Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan.

    Published in:
    Journal of Viral Hepatitis, 2019, v. 26, n. 11, p. 1266, doi. 10.1111/jvh.13170
    By:
    • Ikeda, Hiroki;
    • Watanabe, Tsunamasa;
    • Atsukawa, Masanori;
    • Toyoda, Hidenori;
    • Takaguchi, Koichi;
    • Nakamuta, Makoto;
    • Matsumoto, Nobuyuki;
    • Okuse, Chiaki;
    • Tada, Toshifumi;
    • Tsutsui, Akemi;
    • Yamashita, Naoki;
    • Kondo, Chisa;
    • Hayama, Korenobu;
    • Kato, Keizo;
    • Itokawa, Norio;
    • Arai, Taeang;
    • Shimada, Noritomo;
    • Asano, Toru;
    • Uojima, Haruki;
    • Ogawa, Chikara
    Publication type:
    Article
    37

    Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study.

    Published in:
    Cancers, 2019, v. 11, n. 8, p. 1084, doi. 10.3390/cancers11081084
    By:
    • Kudo, Masatoshi;
    • Ueshima, Kazuomi;
    • Chan, Stephan;
    • Minami, Tomohiro;
    • Chishina, Hirokazu;
    • Aoki, Tomoko;
    • Takita, Masahiro;
    • Hagiwara, Satoru;
    • Minami, Yasunori;
    • Ida, Hiroshi;
    • Takenaka, Mamoru;
    • Sakurai, Toshiharu;
    • Watanabe, Tomohiro;
    • Morita, Masahiro;
    • Ogawa, Chikara;
    • Wada, Yoshiyuki;
    • Ikeda, Masafumi;
    • Ishii, Hiroshi;
    • Izumi, Namiki;
    • Nishida, Naoshi
    Publication type:
    Article
    38

    Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

    Published in:
    Cancers, 2019, v. 11, n. 7, p. 952, doi. 10.3390/cancers11070952
    By:
    • Ueshima, Kazuomi;
    • Nishida, Naoshi;
    • Hagiwara, Satoru;
    • Aoki, Tomoko;
    • Minami, Tomohiro;
    • Chishina, Hirokazu;
    • Takita, Masahiro;
    • Minami, Yasunori;
    • Ida, Hiroshi;
    • Takenaka, Mamoru;
    • Sakurai, Toshiharu;
    • Watanabe, Tomohiro;
    • Morita, Masahiro;
    • Ogawa, Chikara;
    • Hiraoka, Atsushi;
    • Johnson, Philip;
    • Kudo, Masatoshi
    Publication type:
    Article
    39

    Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.

    Published in:
    Investigational New Drugs, 2024, v. 42, n. 5, p. 559, doi. 10.1007/s10637-024-01470-y
    By:
    • Mori, Nami;
    • Tamaki, Nobuharu;
    • Takaki, Shintaro;
    • Tsuji, Keiji;
    • Tada, Toshifumi;
    • Nakamura, Shinichiro;
    • Ochi, Hironori;
    • Mashiba, Toshie;
    • Doisaki, Masao;
    • Marusawa, Hiroyuki;
    • Kobashi, Haruhiko;
    • Fujii, Hideki;
    • Ogawa, Chikara;
    • Nonogi, Michiko;
    • Arai, Hirotaka;
    • Uchida, Yasushi;
    • Urawa, Naohito;
    • Narita, Ryoichi;
    • Akahane, Takehiro;
    • Kondo, Masahiko
    Publication type:
    Article
    40

    Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.

    Published in:
    Investigational New Drugs, 2023, v. 41, n. 2, p. 340, doi. 10.1007/s10637-023-01349-4
    By:
    • Takaki, Shintaro;
    • Kurosaki, Masayuki;
    • Mori, Nami;
    • Tsuji, Keiji;
    • Ochi, Hironori;
    • Marusawa, Hiroyuki;
    • Nakamura, Shinichiro;
    • Tada, Toshifumi;
    • Narita, Ryoichi;
    • Uchida, Yasushi;
    • Akahane, Takehiro;
    • Kondo, Masahiko;
    • Kusakabe, Atsunori;
    • Furuta, Koichiro;
    • Kobashi, Haruhiko;
    • Arai, Hirotaka;
    • Nonogi, Michiko;
    • Tamada, Takashi;
    • Hasebe, Chitomi;
    • Ogawa, Chikara
    Publication type:
    Article
    41
    42

    Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.

    Published in:
    Cancer Medicine, 2025, v. 14, n. 2, p. 1, doi. 10.1002/cam4.70618
    By:
    • Naganuma, Atsushi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hatanaka, Takeshi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishikawa, Hiroki;
    • Nishimura, Takashi;
    • Kawata, Kazuhito;
    • Kosaka, Hisashi
    Publication type:
    Article
    43

    Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 24, p. 21680, doi. 10.1002/cam4.6726
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Yokohama, Keisuke;
    • Nishikawa, Hiroki
    Publication type:
    Article
    44

    Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 7, p. 7772, doi. 10.1002/cam4.5535
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    45

    New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 6, p. 6980, doi. 10.1002/cam4.5495
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Hirooka, Masashi;
    • Takaguchi, Koichi;
    • Atsukawa, Masanori;
    • Fukunishi, Shinya;
    • Itobayashi, Ei;
    • Tsuji, Kunihiko;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Ishikawa, Toru;
    • Yasuda, Satoshi;
    • Ogawa, Chikara;
    • Toyoda, Hidenori;
    • Hatanaka, Takeshi;
    • Nishimura, Takashi;
    • Kakizaki, Satoru
    Publication type:
    Article
    46

    Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 5, p. 5293, doi. 10.1002/cam4.5337
    By:
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Shimada, Noritomo
    Publication type:
    Article
    47

    The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 4, p. 4259, doi. 10.1002/cam4.5294
    By:
    • Hatanaka, Takeshi;
    • Naganuma, Atsushi;
    • Hiraoka, Atsushi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Shimada, Noritomo
    Publication type:
    Article
    48

    Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib.

    Published in:
    Cancer Medicine, 2023, v. 12, n. 1, p. 325, doi. 10.1002/cam4.4854
    By:
    • Hiraoka, Atsushi;
    • Kumada, Takashi;
    • Tada, Toshifumi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    49

    Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Cancer Medicine, 2022, v. 11, n. 20, p. 3796, doi. 10.1002/cam4.4763
    By:
    • Tada, Toshifumi;
    • Kumada, Takashi;
    • Hiraoka, Atsushi;
    • Hirooka, Masashi;
    • Kariyama, Kazuya;
    • Tani, Joji;
    • Atsukawa, Masanori;
    • Takaguchi, Koichi;
    • Itobayashi, Ei;
    • Fukunishi, Shinya;
    • Tsuji, Kunihiko;
    • Ishikawa, Toru;
    • Tajiri, Kazuto;
    • Ochi, Hironori;
    • Yasuda, Satoshi;
    • Toyoda, Hidenori;
    • Ogawa, Chikara;
    • Nishimura, Takashi;
    • Hatanaka, Takeshi;
    • Kakizaki, Satoru
    Publication type:
    Article
    50

    Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

    Published in:
    Journal of Gastroenterology, 2025, v. 60, n. 6, p. 738, doi. 10.1007/s00535-025-02233-z
    By:
    • Aoki, Tomoko;
    • Kudo, Masatoshi;
    • Nishida, Naoshi;
    • Ueshima, Kazuomi;
    • Tsuchiya, Kaoru;
    • Tada, Toshifumi;
    • Morita, Masahiro;
    • Chishina, Hirokazu;
    • Takita, Masahiro;
    • Hagiwara, Satoru;
    • Ida, Hiroshi;
    • Minami, Yasunori;
    • Kuroda, Hidekatsu;
    • Nakamura, Noriaki;
    • Hiraoka, Atsushi;
    • Tomonari, Tetsu;
    • Tani, Joji;
    • Naganuma, Atsushi;
    • Kakizaki, Satoru;
    • Ogawa, Chikara
    Publication type:
    Article